Vaxcell-Bio Therapeutics
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
323990 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 전라남도 화순군 화순읍 산단길 12-55, 화순군
- Website:
- https://vaxcell-bio.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Vaxcell-Bio Therapeutics is a biotechnology company specializing in the research and development of anti-cancer immunotherapies. The company's core R&D is centered on its proprietary Natural Killer (NK) cell and Chimeric Antigen Receptor (CAR) technology platforms, developing advanced CAR-T and CAR-NK cell therapies. Its pipeline targets a range of malignancies, including liver cancer, pancreatic cancer, small cell lung cancer, and other solid tumors. A notable product, Vaxleukin-15, is an approved immunotherapy adjunct for canine lymphoma. The company actively secures intellectual property for its novel methods of manufacturing high-purity immune cells, positioning itself as a key developer in patient-specific cancer treatments.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Vaxcell-Bio Therapeutics and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all Vaxcell-Bio Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Vaxcell-Bio Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
